The Latest Breaking News from FDA

Robert F. Kennedy Jr. discusses President Trump's interest in mifepristone regulation and its safety in medication abortions.

Frito-Lay insists all affected bags are currently off shelves.

Robert F. Kennedy Jr faces a pivotal Senate hearing in which his history with vaccines is being subjected to scrutiny

Learn about the US Department of Health and Human Services and its critical role in promoting public health, advancing medical research, and ensuring acces...

According to the FDA, "Class I" level recalls are used when there is "reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death."

Caroline Kennedy condemns cousin RFK Jr. as a "predator" before his Senate confirmation for HHS, citing his controversial vaccine views, ethical lapses, history of drug addiction, and exploitation of family tragedies.

Biden's FDA pushed a prohibition that disproportionately targeted marginalized communities. Trump's reversal may mark a shift toward smarter drug policy.

This robotic AI stock is a “buy and hold” stock for the long term despite its lofty valuation.

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

Australia recently became the first country to legalize both MDMA and psilocybin-assisted psychiatric therapy

The FDA has recently authorized the sale of Zyn nicotine pouches, marking a pivotal moment in tobacco harm reduction. As concerns about traditional smoking persist, nicotine pouches present a viable alternative for adult smokers. This approval underscores their potential public health benefits, despite challenges surrounding youth appeal.